TRCT
IRMD icon

Tower Research Capital (TRC)’s iRadimed IRMD Stock Holding History

Tower Research Capital (TRC)’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.7K Buy
288
+146
+103% +$14.6K ﹤0.01% 3239
2025
Q4 		$13.8K Sell
142
-248
-64% -$21.3K ﹤0.01% 3389
2025
Q3 		$27.8K Sell
390
-364
-48% -$24.3K ﹤0.01% 3017
2025
Q2 		$45.1K Buy
754
+495
+191% +$27.1K ﹤0.01% 3061
2025
Q1 		$13.6K Buy
259
+7
+3% +$393 ﹤0.01% 3346
2024
Q4 		$13.9K Buy
252
+28
+13% +$1.47K ﹤0.01% 3501
2024
Q3 		$11.3K Sell
224
-713
-76% -$32.9K ﹤0.01% 3676
2024
Q2 		$41.2K Sell
937
-685
-42% -$29.1K ﹤0.01% 3239
2024
Q1 		$71.4K Buy
1,622
+1,154
+247% +$51K ﹤0.01% 2037
2023
Q4 		$22.2K Buy
468
+173
+59% +$7.27K ﹤0.01% 3582
2023
Q3 		$13.1K Buy
295
+65
+28% +$3.02K ﹤0.01% 3829
2023
Q2 		$11K Sell
230
-93
-29% -$4.19K ﹤0.01% 4036
2023
Q1 		$13K Buy
323
+17
+6% +$618 ﹤0.01% 3979
2022
Q4 		$9K Sell
306
-825
-73% -$23.6K ﹤0.01% 4206
2022
Q3 		$34K Buy
1,131
+384
+51% +$13.4K ﹤0.01% 3488
2022
Q2 		$25K Sell
747
-615
-45% -$22K ﹤0.01% 3558
2022
Q1 		$61K Buy
1,362
+124
+10% +$5.74K ﹤0.01% 2582
2021
Q4 		$57K Sell
1,238
-1,807
-59% -$72.9K ﹤0.01% 2662
2021
Q3 		$102K Buy
3,045
+2,537
+499% +$86.3K ﹤0.01% 2386
2021
Q2 		$15K Buy
508
+43
+9% +$1.19K ﹤0.01% 4128
2021
Q1 		$12K Sell
465
-2,170
-82% -$51.8K ﹤0.01% 4262
2020
Q4 		$61K Sell
2,635
-3,601
-58% -$83.2K ﹤0.01% 2899
2020
Q3 		$133K Buy
6,236
+5,183
+492% +$116K ﹤0.01% 2913
2020
Q2 		$24K Buy
1,053
+934
+785% +$20.1K ﹤0.01% 3586
2020
Q1 		$3K Sell
119
-6
-5% -$143 ﹤0.01% 2469
2019
Q4 		$3K Sell
125
-1,899
-94% -$44.4K ﹤0.01% 2925
2019
Q3 		$42K Buy
2,024
+1,057
+109% +$21.6K ﹤0.01% 1921
2019
Q2 		$19K Buy
+967
New +$22.8K ﹤0.01% 2215
2018
Q4 		– Sell
-30
Closed -$1K – 4075
2018
Q3 		$1K Sell
30
-2,457
-99% -$66.3K ﹤0.01% 3596
2018
Q2 		$52K Buy
+2,487
New +$44K ﹤0.01% 1832
2018
Q1 		– Sell
-1,073
Closed -$17K – 3542
2017
Q4 		$17K Sell
1,073
-159
-13% -$2.02K ﹤0.01% 2190
2017
Q3 		$12K Buy
+1,232
New +$11.7K ﹤0.01% 2991
2017
Q1 		– Sell
-1,737
Closed -$19K – 3471
2016
Q4 		$19K Buy
1,737
+388
+29% +$4.18K ﹤0.01% 2197
2016
Q3 		$23K Buy
1,349
+806
+148% +$14.9K ﹤0.01% 1527
2016
Q2 		$12K Buy
543
+144
+36% +$2.59K ﹤0.01% 2657
2016
Q1 		$8K Buy
399
+394
+7,880% +$7.54K ﹤0.01% 2205
2015
Q4 		$0 Sell
5
-1,900
-100% -$53.7K ﹤0.01% 4748
2015
Q3 		$47K Buy
1,905
+29
+2% +$694 ﹤0.01% 1070
2015
Q2 		$44K Buy
1,876
+1,754
+1,438% +$32K ﹤0.01% 1469
2015
Q1 		$2K Sell
122
-2,033
-94% -$30K ﹤0.01% 3782
2014
Q4 		$28K Sell
2,155
-1,270
-37% -$11K ﹤0.01% 1377
2014
Q3 		$24K Buy
+3,425
New +$31K ﹤0.01% 2151

Other funds holding IRMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tower Research Capital (TRC)'s IRMD Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its iRadimed (IRMD) stake by 103% in Q1 2026, buying an estimated $14.6K and bringing the position to 288 shares worth $27.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3239.

Tower Research Capital (TRC) first reported a position in IRMD in Q3 2014 and has held it in 42 quarters since. The position peaked at $133K in Q3 2020. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • Tower Research Capital (TRC) held 288 shares of iRadimed worth $27.7K as of Q1 2026.
  • Tower Research Capital (TRC) bought 146 iRadimed shares in Q1 2026, an estimated $14.6K.
  • iRadimed made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3239 holding.
  • Tower Research Capital (TRC) first reported a position in iRadimed in Q3 2014 and has held it in 42 quarters since.
  • Tower Research Capital (TRC)'s iRadimed position peaked at $133K in Q3 2020.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.